Vol 24, No 2 (2021)
Research paper
Published online: 2021-07-30

open access

Page views 6606
Article views/downloads 579
Get Citation

Connect on Social Media

Connect on Social Media

Sentinel lymph node biopsy in upper tract urothelial cancers: an experience with intraoperative radiotracer injection

Leili Zarifmahmoudi1, Hamidreza Ghorbani2, Ramin Sadeghi1, Salman Soltani2, Kayvan Sadri1, Mahmoud Tavakkoli2, Maliheh Keshvari2
Pubmed: 34382666
Nucl. Med. Rev 2021;24(2):41-45.

Abstract

Background: The feasibility of the sentinel node mapping in upper tract urothelial cancers (UTUC) was evaluated, using a radiotracer as the mapping material.

Material and methods: To identify the sentinel lymph nodes, 37 MBq of [99mTc] phytate was injected in five patients with the renal pelvis or ureter cancer, who were candidates for ureterectomy and lymphadenectomy. The radiotracer was injected in a peritumoral fashion following the surgical exposure of the tumour. The sentinel lymph nodes were detected using a handheld gamma probe.

Results: By intraoperatively injecting the radiotracer immediately after surgical exposure of the tumour, at least one sentinel lymph node could be detected in each patient, and the detection rate was 100%. The location of sentinel nodes was in the paracaval, renal hill, retro-aortic, para-aortic, common iliac, and external iliac areas, which was dependent on the tumour location.

No false-negative case was identified.

Conclusions: Sentinel node mapping is feasible in UTUC. Injection technique (intra-vesical approach vs peri-tumoral injection after exposure of the tumour) and location of the tumour (proximal vs distal) may affect the technique’s feasibility.

Article available in PDF format

View PDF Download PDF file

References

  1. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018; 73(1): 111–122.
  2. Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017; 71(3): 447–461.
  3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1): 7–30.
  4. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000; 50(1): 7–33.
  5. Spiess PE, Agarwal N, Bangs R, et al. Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15(10): 1240–1267.
  6. Leow JJ, Liu Z, Tan TW, et al. Optimal management of upper tract urothelial carcinoma: current perspectives. Onco Targets Ther. 2020; 13: 1–15.
  7. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3): 666–675.
  8. Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol. 2008; 53(4): 720–731.
  9. Zarifmahmoudi L, Ghorbani H, Sadri K, et al. Sentinel node biopsy in urothelial carcinoma of the bladder: systematic review and meta-analysis. Urol Int. 2019; 103(4): 373–382.
  10. Hassanzade M, Attaran M, Treglia G, et al. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013; 130(1): 237–245.
  11. Sadeghi R, Gholami H, Zakavi SR, et al. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol. 2012; 187(1): 25–31.
  12. Kadkhodayan S, Hasanzadeh M, Treglia G, et al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. Eur J Surg Oncol. 2015; 41(1): 1–20.
  13. Sadeghi R, Tabasi KT, Bazaz SMM, et al. Sentinel node mapping in the prostate cancer. Meta-analysis. Nuklearmedizin. 2011; 50(3): 107–115.
  14. Ansari M, Rad MA, Hassanzadeh M, et al. Sentinel node biopsy in endometrial cancer: systematic review and meta-analysis of the literature. Eur J Gynaecol Oncol. 2013; 34(5): 387–401.
  15. Sadeghi R. Sentinel node mapping diagnostic studies warrant a unique reporting criteria: comment on Xiong et al. systematic review. Eur J Surg Oncol. 2014; 40(8): 1025–1026.
  16. Zarifmahmoudi L, Sadeghi R. Re: radio-guided lymph node mapping in bladder cancer using SPECT/CT and intraoperative γ-Probe methods. Clin Nucl Med. 2017; 42(4): 327.
  17. Ramin S, Azar FP, Malihe H. Methylene blue as the safest blue dye for sentinel node mapping: emphasis on anaphylaxis reaction. Acta Oncol. 2011; 50(5): 729–731.
  18. Jangjoo A, Forghani MN, Mehrabibahar M, et al. Anaphylaxis reaction of a breast cancer patient to methylene blue during breast surgery with sentinel node mapping. Acta Oncol. 2010; 49(6): 877–878.
  19. Sadeghi R, Forghani MN, Memar B, et al. How long the lymphoscintigraphy imaging should be continued for sentinel lymph node mapping? Ann Nucl Med. 2009; 23(6): 507–510.
  20. Aliakbarian M, Memar B, Jangjoo A, et al. Factors influencing the time of sentinel node visualization in breast cancer patients using intradermal injection of the radiotracer. Am J Surg. 2011; 202(2): 199–202.
  21. Jangjoo A, Forghani MN, Mehrabibahar M, et al. Comparison of early and delayed lymphoscintigraphy images of early breast cancer patients undergoing sentinel node mapping. Nucl Med Commun. 2010; 31(6): 521–525.
  22. Kondo T, Nakazawa H, Ito F, et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 2007; 178(4 Pt 1): 1212–1217.
  23. Brausi MA, Gavioli M, De Luca G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol. 2007; 52(5): 1414–1418.
  24. Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol. 2008; 53(4): 794–802.
  25. Roscigno M, Shariat SF, Freschi M, et al. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology. 2009; 74(5): 1070–1074.
  26. Roscigno M, Shariat SF, Margulis V, et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol. 2009; 56(3): 512–518.
  27. Miyake H, Hara I, Gohji K, et al. The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. Br J Urol. 1998; 82(4): 494–498.
  28. Roscigno M, Brausi M, Heidenreich A, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. European Urology. 2011; 60(4): 776–783.
  29. Secin FP, Koppie TM, Salamanca JI, et al. Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. Int J Urol. 2007; 14(1): 26–32.
  30. Lughezzani G, Jeldres C, Isbarn H, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology. 2010; 75(1): 118–124.